One of the major aims of allogeneic haemopoietic stem cell transplantation has been the
effective suppression of graft-versus-host disease (GVHD) without loss of a graft-versus …

Cyclosporine A (CSA) and methotrexate (MTX) is the standard graft-versus-host disease
(GVHD) prophylaxis regimen for matched sibling donor (MSD) allogeneic hematopoietic cell …

We hypothesized that reducing the dosage of prophylaxis for graft-versus-host disease
(GVHD) would reduce the risk of relapse and toxicity after bone marrow transplantation …

Fifty‐two patients with chronic myelogenous leukemia (CML) who underwent bone marrow
transplantation (BMT) at Huddinge Hospital were analyzed retrospectively regarding type of …

A total of 1634 recipients of HLA-identical sibling bone marrow with acute leukemia were
treated with the combination of cyclosporin A (CsA) and methotrexate as prophylaxis against …

After the transplantation of unmodified marrow from human leukocyte antigen-matched
unrelated donors receiving cyclosporine (CSP) and methotrexate (MTX), the incidence of …

Fifty-seven patients undergoing bone marrow transplantation were randomly assigned to
receive either cyclosporin A (CsA, n= 26) or methotrexate, followed by rescue with folinic …

We have previously demonstrated a decrease in the incidence of acute graft-versus-host
disease (GVHD) with the addition of methotrexate (MTX) to cyclosporine (CSP) and …

The effect of graft-versus-host disease (GVHD) on relapse incidence and survival has been
analyzed in several studies, but previous studies included heterogeneous patients …

From May 1985 to July 1989, 76 patients with leukemia (30 acute myelogenous leukemia,
24 acute lymphoblastic leukemia and 22 chronic myeloid leukemia) were randomized to …